Evidence of peptide vaccines eliciting anti-tumor responses in GBM and NSCLC suggests the potential for the development of robust vaccines for other EGFR-mutant cancers, including LUAD, GBM, CRAD, and HNSCC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.